247 related articles for article (PubMed ID: 24238045)
1. MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors.
Patel D; Boufraqech M; Jain M; Zhang L; He M; Gesuwan K; Gulati N; Nilubol N; Fojo T; Kebebew E
Surgery; 2013 Dec; 154(6):1224-8; discussion 1229. PubMed ID: 24238045
[TBL] [Abstract][Full Text] [Related]
2. Analysis of circulating microRNAs in adrenocortical tumors.
Szabó DR; Luconi M; Szabó PM; Tóth M; Szücs N; Horányi J; Nagy Z; Mannelli M; Patócs A; Rácz K; Igaz P
Lab Invest; 2014 Mar; 94(3):331-9. PubMed ID: 24336071
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA Expression Profiling in Adrenal Myelolipoma.
Decmann A; Perge P; Nyíro G; Darvasi O; Likó I; Borka K; Micsik T; Tóth Z; Bancos I; Pezzani R; Iacobone M; Patócs A; Igaz P
J Clin Endocrinol Metab; 2018 Sep; 103(9):3522-3530. PubMed ID: 29982598
[TBL] [Abstract][Full Text] [Related]
4. Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas.
Hofland J; Feelders RA; van der Wal R; Kerstens MN; Haak HR; de Herder WW; de Jong FH
Eur J Endocrinol; 2012 Feb; 166(2):281-9. PubMed ID: 22127493
[TBL] [Abstract][Full Text] [Related]
5. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients.
Chabre O; Libé R; Assie G; Barreau O; Bertherat J; Bertagna X; Feige JJ; Cherradi N
Endocr Relat Cancer; 2013 Aug; 20(4):579-94. PubMed ID: 23756429
[TBL] [Abstract][Full Text] [Related]
6. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma.
Özata DM; Caramuta S; Velázquez-Fernández D; Akçakaya P; Xie H; Höög A; Zedenius J; Bäckdahl M; Larsson C; Lui WO
Endocr Relat Cancer; 2011 Oct; 18(6):643-55. PubMed ID: 21859927
[TBL] [Abstract][Full Text] [Related]
7. Circulating microRNAs in adrenal tumors.
Igaz P
Curr Opin Endocrinol Diabetes Obes; 2019 Jun; 26(3):155-159. PubMed ID: 30801265
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours.
Schmitz KJ; Helwig J; Bertram S; Sheu SY; Suttorp AC; Seggewiss J; Willscher E; Walz MK; Worm K; Schmid KW
J Clin Pathol; 2011 Jun; 64(6):529-35. PubMed ID: 21471143
[TBL] [Abstract][Full Text] [Related]
9. Analysis of circulating extracellular vesicle-associated microRNAs in cortisol-producing adrenocortical tumors.
Perge P; Decmann Á; Pezzani R; Bancos I; Fassina A; Luconi M; Canu L; Tóth M; Boscaro M; Patócs A; Igaz P
Endocrine; 2018 Feb; 59(2):280-287. PubMed ID: 29299796
[TBL] [Abstract][Full Text] [Related]
10. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers.
Wang C; Sun Y; Wu H; Zhao D; Chen J
Histopathology; 2014 Mar; 64(4):567-76. PubMed ID: 24102952
[TBL] [Abstract][Full Text] [Related]
11. Analysis of IGF and IGFBP as prognostic serum biomarkers for adrenocortical carcinoma.
Patel D; Ellis R; Howard B; Boufraqech M; Gara SK; Zhang L; Quezado MM; Nilubol N; Kebebew E
Ann Surg Oncol; 2014 Oct; 21(11):3541-7. PubMed ID: 24833102
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing reveals microRNA markers of adrenocortical tumors malignancy.
Koperski Ł; Kotlarek M; Świerniak M; Kolanowska M; Kubiak A; Górnicka B; Jażdżewski K; Wójcicka A
Oncotarget; 2017 Jul; 8(30):49191-49200. PubMed ID: 28423361
[TBL] [Abstract][Full Text] [Related]
13. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.
Sbiera S; Schmull S; Assie G; Voelker HU; Kraus L; Beyer M; Ragazzon B; Beuschlein F; Willenberg HS; Hahner S; Saeger W; Bertherat J; Allolio B; Fassnacht M
J Clin Endocrinol Metab; 2010 Oct; 95(10):E161-71. PubMed ID: 20660055
[TBL] [Abstract][Full Text] [Related]
14. Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma.
Liu-Chittenden Y; Patel D; Gaskins K; Giordano TJ; Assie G; Bertherat J; Kebebew E
J Clin Endocrinol Metab; 2016 Sep; 101(9):3345-52. PubMed ID: 27336360
[TBL] [Abstract][Full Text] [Related]
15. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
16. Comparison of plasma and urinary microRNA-483-5p for the diagnosis of adrenocortical malignancy.
Decmann A; Bancos I; Khanna A; Thomas MA; Turai P; Perge P; Pintér JZ; Tóth M; Patócs A; Igaz P
J Biotechnol; 2019 May; 297():49-53. PubMed ID: 30940435
[TBL] [Abstract][Full Text] [Related]
17. [Pathogenic and diagnostic roles of microRNAs in adrenocortical tumours].
Nagy Z; Decmann Á; Perge P; Igaz P
Orv Hetil; 2018 Feb; 159(7):245-251. PubMed ID: 29429354
[TBL] [Abstract][Full Text] [Related]
18. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis.
Tömböl Z; Szabó PM; Molnár V; Wiener Z; Tölgyesi G; Horányi J; Riesz P; Reismann P; Patócs A; Likó I; Gaillard RC; Falus A; Rácz K; Igaz P
Endocr Relat Cancer; 2009 Sep; 16(3):895-906. PubMed ID: 19546168
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy.
Patterson EE; Holloway AK; Weng J; Fojo T; Kebebew E
Cancer; 2011 Apr; 117(8):1630-9. PubMed ID: 21472710
[TBL] [Abstract][Full Text] [Related]
20. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
Zhang K; Wang YW; Wang YY; Song Y; Zhu J; Si PC; Ma R
Gene; 2017 Jul; 619():10-20. PubMed ID: 28359916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
